Yuhe Lei

1.5k total citations · 1 hit paper
28 papers, 1.2k citations indexed

About

Yuhe Lei is a scholar working on Molecular Biology, Cancer Research and Epidemiology. According to data from OpenAlex, Yuhe Lei has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 8 papers in Cancer Research and 7 papers in Epidemiology. Recurrent topics in Yuhe Lei's work include MicroRNA in disease regulation (5 papers), Natural product bioactivities and synthesis (5 papers) and Autophagy in Disease and Therapy (5 papers). Yuhe Lei is often cited by papers focused on MicroRNA in disease regulation (5 papers), Natural product bioactivities and synthesis (5 papers) and Autophagy in Disease and Therapy (5 papers). Yuhe Lei collaborates with scholars based in China, United States and Hong Kong. Yuhe Lei's co-authors include Dongmei Zhang, Wen‐Cai Ye, Nan Yao, Nan Hu, Yingjie Li, Zhe‐Sheng Chen, Chenran Wang, Lijuan Deng, Ming Qi and Jiaxu Chen and has published in prestigious journals such as Biochemical Pharmacology, Journal of Ethnopharmacology and Life Sciences.

In The Last Decade

Yuhe Lei

26 papers receiving 1.2k citations

Hit Papers

Autophagy and multidrug resistance in cancer 2017 2026 2020 2023 2017 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuhe Lei China 15 795 347 332 217 111 28 1.2k
Nan Yao China 18 854 1.1× 331 1.0× 306 0.9× 266 1.2× 129 1.2× 31 1.3k
Shuo Deng Singapore 11 786 1.0× 475 1.4× 273 0.8× 195 0.9× 103 0.9× 17 1.4k
Mohamed Elgendy Italy 13 766 1.0× 413 1.2× 209 0.6× 199 0.9× 113 1.0× 21 1.2k
Yongbin Chen China 10 577 0.7× 249 0.7× 220 0.7× 165 0.8× 85 0.8× 14 994
Arumugam Nagalingam United States 21 875 1.1× 501 1.4× 431 1.3× 410 1.9× 117 1.1× 37 1.7k
Zhenzhen Huang China 5 840 1.1× 610 1.8× 331 1.0× 170 0.8× 63 0.6× 10 1.2k
Daniela Carlisi Italy 26 1.2k 1.5× 164 0.5× 508 1.5× 283 1.3× 96 0.9× 54 1.7k
Kewal Kumar Mahapatra India 17 781 1.0× 490 1.4× 237 0.7× 111 0.5× 118 1.1× 30 1.2k
Yuan‐Zheng Xia China 22 794 1.0× 130 0.4× 199 0.6× 262 1.2× 86 0.8× 47 1.2k
Enrico Desideri Italy 20 665 0.8× 278 0.8× 339 1.0× 122 0.6× 69 0.6× 32 1.2k

Countries citing papers authored by Yuhe Lei

Since Specialization
Citations

This map shows the geographic impact of Yuhe Lei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuhe Lei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuhe Lei more than expected).

Fields of papers citing papers by Yuhe Lei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuhe Lei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuhe Lei. The network helps show where Yuhe Lei may publish in the future.

Co-authorship network of co-authors of Yuhe Lei

This figure shows the co-authorship network connecting the top 25 collaborators of Yuhe Lei. A scholar is included among the top collaborators of Yuhe Lei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuhe Lei. Yuhe Lei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Sheng, Fangyuan Yang, Jiaxin Luo, et al.. (2025). Erianin inhibits the proliferation and stemness of pancreatic cancer cells by interacting with MEK1/2. Biochemical Pharmacology. 239. 117046–117046. 1 indexed citations
3.
Shi, Chuan-Jian, Fengxiang Pang, Yuhe Lei, et al.. (2024). 5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1/SLC7A11-mediated ferroptosis. Drug Resistance Updates. 78. 101181–101181. 25 indexed citations
4.
Bai, Liangliang, Linping Wu, Changsheng Zhang, et al.. (2024). Replenishment of mitochondrial Na+ and H+ by ionophores potentiates cutaneous wound healing in diabetes. Materials Today Bio. 26. 101056–101056. 3 indexed citations
5.
Lin, Zhongxiao, Jianmei Zhang, Yun Chen, et al.. (2023). Virtual screening combined with experimental verification reveals the potential mechanism of Fuzitang decoction against Gouty Arthritis. Heliyon. 9(12). e22650–e22650. 1 indexed citations
6.
Lin, Jiapeng, Maohua Huang, Lei Chen, et al.. (2023). Periplocin inhibits hepatocellular carcinoma progression and reduces the recruitment of MDSCs through AKT/NF-κB pathway. Life Sciences. 324. 121715–121715. 11 indexed citations
7.
Chen, Lijuan, Yuhe Lei, Song Rong, et al.. (2023). Shugan Jiangzhi Decoction Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) via Regulating AMPK/PPAR Signaling Pathway. Letters in Drug Design & Discovery. 21(13). 2740–2750.
8.
Wang, Xiaokang, et al.. (2023). Therapy resistance in neuroblastoma: Mechanisms and reversal strategies. Frontiers in Pharmacology. 14. 1114295–1114295. 28 indexed citations
10.
Wang, Xiaokang, et al.. (2023). Functions, mechanisms, and therapeutic implications of noncoding RNA in acute myeloid leukemia. Fundamental Research. 5(4). 1781–1794. 7 indexed citations
11.
Lei, Yuhe, et al.. (2022). The MicroRNA-Based Strategies to Combat Cancer Chemoresistance via Regulating Autophagy. Frontiers in Oncology. 12. 841625–841625. 19 indexed citations
12.
Gan, Hua, Yuhe Lei, Naijun Yuan, et al.. (2021). Circular RNAs in depression: Biogenesis, function, expression, and therapeutic potential. Biomedicine & Pharmacotherapy. 137. 111244–111244. 25 indexed citations
13.
Lei, Yuhe, et al.. (2021). Bioinformatics and Network Pharmacology-Based Approaches to Explore the Potential Mechanism of the Antidepressant Effect of Cyperi Rhizoma through Soothing the Liver. Evidence-based Complementary and Alternative Medicine. 2021. 1–13. 5 indexed citations
14.
Huang, Maohua, et al.. (2021). New Insights Into the Regulatory Roles of Extracellular Vesicles in Tumor Angiogenesis and Their Clinical Implications. Frontiers in Cell and Developmental Biology. 9. 791882–791882. 17 indexed citations
15.
Deng, Lijuan, Yong Li, Ming Qi, et al.. (2020). Molecular mechanisms of bufadienolides and their novel strategies for cancer treatment. European Journal of Pharmacology. 887. 173379–173379. 37 indexed citations
16.
Deng, Lijuan, Yuhe Lei, Dongmei Zhang, et al.. (2020). 1β–OH–arenobufagin induces mitochondrial apoptosis in hepatocellular carcinoma through the suppression of mTOR signaling pathway. Journal of Ethnopharmacology. 266. 113443–113443. 15 indexed citations
17.
Lei, Yuhe, Yuqing Huang, Yueyue Chen, et al.. (2020). Digitoxin inhibits proliferation of multidrug‑resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. Oncology Letters. 20(4). 71–71. 12 indexed citations
18.
Li, Yingjie, Yuhe Lei, Nan Yao, et al.. (2017). Autophagy and multidrug resistance in cancer. Chinese Journal of Cancer. 36(1). 52–52. 559 indexed citations breakdown →
19.
Yao, Nan, Yingjie Li, Yuhe Lei, et al.. (2016). A piperazidine derivative of 23-hydroxy betulinic acid induces a mitochondria-derived ROS burst to trigger apoptotic cell death in hepatocellular carcinoma cells. Journal of Experimental & Clinical Cancer Research. 35(1). 192–192. 27 indexed citations
20.
Tian, Hai‐Yan, Dongmei Zhang, Yuhe Lei, et al.. (2015). Bufadienolides with cytotoxic activity from the skins of Bufo bufo gargarizans. Fitoterapia. 105. 7–15. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026